174 related articles for article (PubMed ID: 20002849)
21. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
Di Maio M
Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
[TBL] [Abstract][Full Text] [Related]
22. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
[TBL] [Abstract][Full Text] [Related]
23. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
Kelly K; Huang C
J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
[TBL] [Abstract][Full Text] [Related]
24. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Solomon B; Wilner KD; Shaw AT
Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
[TBL] [Abstract][Full Text] [Related]
25. Toxicity of targeted therapy in non-small-cell lung cancer management.
Ricciardi S; Tomao S; de Marinis F
Clin Lung Cancer; 2009 Jan; 10(1):28-35. PubMed ID: 19289369
[TBL] [Abstract][Full Text] [Related]
26. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
27. The emerging role of biomarkers in advanced non-small-cell lung cancer.
Socinski MA
Clin Lung Cancer; 2010 May; 11(3):149-59. PubMed ID: 20439190
[TBL] [Abstract][Full Text] [Related]
28. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
Takeda M; Nakagawa K
Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
[TBL] [Abstract][Full Text] [Related]
29. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Langer CJ; Mok T; Postmus PE
Cancer Treat Rev; 2013 May; 39(3):252-60. PubMed ID: 22703830
[TBL] [Abstract][Full Text] [Related]
30. Implications of key trials in advanced nonsmall cell lung cancer.
Bonomi PD
Cancer; 2010 Mar; 116(5):1155-64. PubMed ID: 20087963
[TBL] [Abstract][Full Text] [Related]
31. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
Gridelli C; Rossi A
Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
[TBL] [Abstract][Full Text] [Related]
32. Optimizing chemotherapy and targeted agent combinations in NSCLC.
Lynch T; Kim E
Lung Cancer; 2005 Dec; 50 Suppl 2():S25-32. PubMed ID: 16557671
[TBL] [Abstract][Full Text] [Related]
33. [Molecular targeted therapy in lung cancer].
Azuma K; Nakagawa K
Nihon Rinsho; 2010 Oct; 68(10):1848-53. PubMed ID: 20954328
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy in lung cancer: the good, the bad, and the ugly.
Gadgeel SM
Clin Lung Cancer; 2009 Jan; 10(1):10-2. PubMed ID: 19289366
[No Abstract] [Full Text] [Related]
35. Targeted therapy for NSCLC: ALK inhibition.
Pearson R; Kolesar JM
J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
[TBL] [Abstract][Full Text] [Related]
36. Her2-targeted therapies in non-small cell lung cancer.
Swanton C; Futreal A; Eisen T
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4377s-4383s. PubMed ID: 16857814
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in targeted therapy for non-small cell lung cancer.
Ramalingam S; Belani CP
Expert Opin Ther Targets; 2007 Feb; 11(2):245-57. PubMed ID: 17227238
[TBL] [Abstract][Full Text] [Related]
38. Molecularly-targeted therapies for non-small cell lung cancer.
Ramalingam S; Belani CP
Expert Opin Pharmacother; 2005 Dec; 6(15):2667-79. PubMed ID: 16316305
[TBL] [Abstract][Full Text] [Related]
39. Pleural effusion in lung cancer: more questions than answers.
Froudarakis ME
Respiration; 2012; 83(5):367-76. PubMed ID: 22584211
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.
Macarulla T; Casado E; Ramos FJ; Valverde C; Tabernero J
Onkologie; 2006 Mar; 29(3):99-105. PubMed ID: 16514271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
